DF/HCC Program Affiliation

Cancer Imaging
Prostate Cancer

Research Abstract

Our lab develops novel PET radiopharmaceuticals used in the PET imaging for diagnosis and therapy monitoring of cancers. We develop PET radiotracers that target biochemical processes that are altered in neoplasms. We have focussed on small molecular substrate molecules such as analogs of glucose, fatty acids, and choline. Our work with fluorine-18 labeled choline has shown particular promise for imaging of prostate cancer.

Publications

• Bansal A, Shuyan W, Hara T, Harris RA, Degrado TR.Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats.Eur J Nucl Med Mol Imaging 2008 Feb 9.
  18264706
• Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN.Cancer imaging with fluorine-18-labeled choline derivatives.Semin Nucl Med 2007 Nov;37(6):420-8.
  17920349
• Hara T, Bansal A, DeGrado TR.Choline transporter as a novel target for molecular imaging of cancer.Mol Imaging 2006 Oct-Dec;5(4):498-509.
  17150162
• Hara T, Bansal A, DeGrado TR.Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.Nucl Med Biol 2006 Nov;33(8):977-84.
  17127170